Pathology - Research and Practice, Год журнала: 2024, Номер 258, С. 155333 - 155333
Опубликована: Апрель 27, 2024
Язык: Английский
Pathology - Research and Practice, Год журнала: 2024, Номер 258, С. 155333 - 155333
Опубликована: Апрель 27, 2024
Язык: Английский
Pathology - Research and Practice, Год журнала: 2024, Номер 255, С. 155180 - 155180
Опубликована: Янв. 30, 2024
Язык: Английский
Процитировано
8International Journal of Biological Macromolecules, Год журнала: 2025, Номер 301, С. 140144 - 140144
Опубликована: Янв. 21, 2025
Язык: Английский
Процитировано
1Small, Год журнала: 2025, Номер unknown
Опубликована: Янв. 22, 2025
Abstract In cancer research and personalized medicine, mesoporous silica nanoparticles (MSNs) have emerged as a significant breakthrough in both treatment diagnosis. MSNs offer targeted drug delivery, enhancing therapeutic effectiveness while minimizing adverse effects on healthy cells. Due to their unique characteristics, provide maximizing with minimal The review thoroughly investigates the role of potent carriers, noted for high drug‐loading capacity controlled release, which significantly improves permeability retention. Additionally, it discusses surface modification techniques that enable target cells precisely. manuscript provides comprehensive insights into various MSN applications, including diagnosis, design advanced biosensors, development conventional stimuli‐responsive delivery platforms. Special focus is given stimuli‐triggered systems, responsive internal stimuli (e.g., pH, redox, enzyme) external temperature, magnetic field, light, ultrasound), highlighting cutting‐edge progress technology. delves immunogenicity biosafety aspects MSNs, underscoring potential clinical translation. Besides summarizing current state oncology, this also illuminates path future advancements applications.
Язык: Английский
Процитировано
1Pathology - Research and Practice, Год журнала: 2023, Номер 253, С. 155019 - 155019
Опубликована: Дек. 7, 2023
Язык: Английский
Процитировано
20Pathology - Research and Practice, Год журнала: 2024, Номер 256, С. 155260 - 155260
Опубликована: Март 11, 2024
Язык: Английский
Процитировано
7Pathology - Research and Practice, Год журнала: 2024, Номер 257, С. 155282 - 155282
Опубликована: Апрель 1, 2024
Язык: Английский
Процитировано
7Pathology - Research and Practice, Год журнала: 2024, Номер 256, С. 155224 - 155224
Опубликована: Фев. 23, 2024
Язык: Английский
Процитировано
6Heliyon, Год журнала: 2024, Номер 10(8), С. e29274 - e29274
Опубликована: Апрель 1, 2024
Combination therapy is a highly successful way to address the limitations of using single treatment method and improve therapy's overall efficacy. In this study, we developed unique hollow mesoporous silica nanoparticle (HMSN) coated with folic acid (FA)-modified bovine serum albumin (FA-BSA). This nanoparticle, referred as HFB, was designed target cancer cells release dual therapeutic drugs, Indocyanine green (ICG) Paclitaxel (PTX), in response specific stimuli termed HFB@IP. The BSA protein acts "gatekeeper" prevent early drug releases cargo leakage by detaching from reaction GSH. FA facilitates targeted transport into that express folate receptors (FR), enhancing effectiveness chemo-photodynamic (PDT). nanocarrier demonstrated vitro pH/redox-triggered HFB@IP due breaking imine bonds between aldehyde-functionalized HMSN (CHO-HMSN) FA-BSA disulfide bond inside BSA. addition, various biological assessments, including cell uptake experiments, effectively targets SGC-7901 induces apoptosis vitro. Further, it exhibits remarkable efficiency synergistically killing through therapy, indicated combination index (CI) 0.328. results showed combining biodegradable stimuli-responsive molecules could offer promising approach for precise treating gastric cancer, allowing controlled drugs necessary.
Язык: Английский
Процитировано
5Journal of Drug Delivery Science and Technology, Год журнала: 2024, Номер 93, С. 105447 - 105447
Опубликована: Фев. 2, 2024
Язык: Английский
Процитировано
4Biogerontology, Год журнала: 2025, Номер 26(1)
Опубликована: Янв. 20, 2025
Язык: Английский
Процитировано
0